Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Gotoga in conjunction with acquisition of Hope
Mandate

Vinge advises Gotoga in conjunction with acquisition of Hope

November 23, 2018 M&A

Vinge has advised the newly-formed company Gotoga, where the ownership structure consists of the existing majority owner in Whyred, in conjunction with its acquisition of the Swedish parent company Hope

Up until now, Hope has been owned by Ann Ringstrand and Stefan Söderberg, who founded the company in 2001, as well as the private equity company Varenne. Over the years, Hope has distinguished itself through its clear silhouettes and its sharp and distinctive designs, and at the beginning of 2018, the company’s designer Frida Bard was awarded the prestigious award Designer of the Year at the Elle gala. 

Vinge’s team consisted of partner Daniel Rosvall together with associates Samra Baytar and Elsie Nassar.
 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024